Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
Year: 2021
Type: article
Abstract: INTRODUCTION: Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data. METHODS: Pretreated (cohort B) and treatment-naive (cohort C) patients with BRAF V600E-mutant mNSCLC received dabrafenib 150 mg twice daily and trametinib 2 mg once daily. The primary end point was investigator-assessed overall response rate per Response Evaluation Criteria in Solid Tumors version 1.1. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: At data cutoff, for cohorts B (57 patients) and C (36 patients), the median follow-up was 16.6 (range: 0.5-78.5) and 16.3 (range: 0.4-80) months, overall response rate (95% confidence interval [CI]) was 68.4% (54.8-80.1) and 63.9% (46.2-79.2), median progression-free survival (95% CI) was 10.2 (6.9-16.7) and 10.8 (7.0-14.5) months, and median overall survival (95% CI) was 18.2 (14.3-28.6) and 17.3 (12.3-40.2) months, respectively. The 4- and 5-year survival rates were 26% and 19% in pretreated patients and 34% and 22% in treatment-naive patients, respectively. A total of 17 patients (18%) were still alive. The most frequent adverse event was pyrexia (56%). Exploratory genomic analysis indicated that the presence of coexisting genomic alterations might influence clinical outcomes in these patients; however, these results require further investigation. CONCLUSIONS: Dabrafenib plus trametinib therapy was found to have substantial and durable clinical benefit, with a manageable safety profile, in patients with BRAF V600E-mutant mNSCLC, regardless of previous treatment.
Source: Journal of Thoracic Oncology
Institutions: Institut Gustave Roussy, Fondation Gustave Roussy, University Medical Center Groningen, University of Groningen, Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Hôpital Larrey, Seoul National University, Seoul National University Hospital, Hôpitaux Universitaires de Strasbourg, Centre National de la Recherche Scientifique, Inserm, Aix-Marseille Université, Centre de Recherche en Cancérologie de Marseille, Fred Hutch Cancer Center, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Baylor University Medical Center, Novartis (United States), Novartis (Switzerland), Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: dabrafenib, trametinib, BRAF V600E mutation, metastatic non-small cell lung cancer, combination targeted therapy, overall survival, progression-free survival, overall response rate, long-term survival, genetic alterations, co-occurring mutations, fever, treatment-naive patients, previously treated patients, durable response, drug safety, BRAF inhibitor resistance, MAPK signaling
Open Access status: hybrid
Estimated APC paid: $2,800
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Spectrum Pharmaceuticals, Celgene, AbbVie, Takeda Pharmaceuticals U.S.A., Novartis Pharmaceuticals Corporation, Merck KGaA, Exelixis, Les Laboratories Pierre Fabre, Society for Academic Continuing Medical Education, Incyte, G1 Therapeutics, Daiichi-Sankyo, Korea Health Industry Development Institute, MedImmune, Genentech, Samsung, EMD Serono, Novartis Pharma, Merck Sharp and Dohme, Chugai Pharmaceutical, Janssen Pharmaceuticals, Daiichi Sankyo Europe
OpenAlex ID: W3193499394
